You are here

  • Home
  • Archive
  • Volume 33, Issue Suppl 4
  • PR037/#494  Pre-treatment systemic inflammatory markers predict survival in endometrial cancer: a Japanese gynaecologic oncology group (JGOG) 2043 exploratory data analysis

Article Text

Article menu

Download PDFPDF

Featured Posters: Poster Rounds with the Professors
AS04. Endometrial/Uterine corpus cancers
PR037/#494  Pre-treatment systemic inflammatory markers predict survival in endometrial cancer: a Japanese gynaecologic oncology group (JGOG) 2043 exploratory data analysis
Free
  1. Shin Nishio1,
  2. Kenta Murotani2,
  3. Wataru Yamagami3,
  4. Shiro Suzuki4,
  5. Hidekatsu Nakai5,
  6. Kazuyoshi Kato6,
  7. Hideki Tokunaga7,
  8. Hiroyuki Nomura8,
  9. Yoshihito Yokoyama9 and
  10. Kazuhiro Takehara10
  1. 1Kurume University School of Medicine, Obstetrics And Gynecology, Kurume, Japan
  2. 2Kurume University School of Medicine, Biostatistics Center, Kurume, Japan
  3. 3Keio University School of Medicine, Department of Gynecologic Oncology, Tokyo, Japan
  4. 4Aichi Cancer Center, Gynecology, Nagoya, Japan
  5. 5Kindai University, Department of Obstetrics and Gynecology, Osakasayama, Japan
  6. 6Kitasato University School of Medicine, Obstetrics and Gynecology, Sagamihara, Japan
  7. 7Tohoku University Graduate School of Medicine, Obstetrics and Gynecology, Sendai, Japan
  8. 8Fujita Health University, Department of Obstetrics and Gynecology, Toyoake, Japan
  9. 9Hirosaki University, Department of Obstetrics and Gynecology, Hirosaki, Japan
  10. 10National Hospital Organization Shikoku Cancer Center, Department Of Gynecologic Oncology, Matsuyama, Japan

Abstract

Introduction Inflammation predisposes patients to tumorigenesis by damaging DNA, stimulating angiogenesis, and potentiating pro-proliferative and anti-apoptotic processes. This study investigated whether pre-treatment systemic inflammatory markers (PTSIMs) are associated with survival outcomes in endometrial cancer (EC) patients.

Methods Women with EC were recruited to the JGOG 2043 study. PTSIMs including neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and hemoglobin, albumin, lymphocyte, and platelet (HALP) score were analysed in terms of clinicopathological factors, progression-free survival (PFS), and overall survival (OS). Optimal cut-off values for NLR, PLR, and HALP score were determined using the web application Cutoff Finder for PFS and OS. Survival estimates were calculated using the Kaplan-Meier method.

Results In total, 712 patients were enrolled with a median age of 59 years and median body mass index (BMI) of 22.4 kg/m2. The optimal cut-off values for PFS were 1.478 for NLR, 0.01695 for PLR, and 35.52 for HALP score. Similarly, the optimal cut-off values for OS were 1.88 for NLR, 0.02623 for PLR, and 19.87 for HALP score. Regarding the optimal cut-off values for PFS, NLR was associated with BMI; PLR with age, BMI, and stage; and HALP score with BMI, stage, and lymph node metastasis. For the optimal cut-offs for OS, NLR was associated with BMI, PLR, and BMI; and HALP score was associated with age and BMI. In PFS, HALP score was the prognostic factor. In OS, PLR and HALP score were prognostic factors.

Conclusion/Implications PTSIMs are associated with survival outcomes in EC. In particular, HALP score was a prognostic factor for both PFS and OS.

https://doi.org/10.1136/ijgc-2023-IGCS.79

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.